Transforming Intratumor Bacteria into Immunopotentiators to Reverse Cold Tumors for Enhanced Immuno-chemodynamic Therapy of Triple-Negative Breast Cancer

Liu, Xuemeng; Sun, Mengyu; Pu, Fang; Ren, Jinsong; Qu, Xiaogang

doi:10.1021/jacs.3c09472

Cited by 12 publications

(4 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…40,67 Recently, a study reports a nanoparticle that precisely targets TNBC tumor tissue and converts intratumor bacteria into immune enhancers, thereby significantly enhancing the effect of TNBC immunotherapy. 68 This study greatly demonstrates the feasibility of trigging the immune system in future immunotherapy and opens up more possibilities for the choice.…”

Section: Discussionmentioning

confidence: 76%

Development and verification of a novel immunogenic cell death‐related signature for predicting the prognosis and immune infiltration in triple‐negative breast cancer

Li,

Yang

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundInsufficient understanding of the pathogenesis and tumor immunology of triple‐negative breast cancer (TNBC) has limited the development of immunotherapy. The importance of tumor microenvironment (TME) in immunotyping, prognostic assessment and immunotherapy efficacy of cancer has been emphasized, however, potential immunogenic cell death (ICD) related genes function in TME of TNBC has been rarely investigated.AimsTo initially explore the role and related mechanisms of ICD in TNBC, especially the role played in the TME of TNBC, and to identify different relevant subtypes based on ICD, and then develop an ICD‐related risk score to predict each TNBC patient TME status, prognosis and immunotherapy response.Methods and resultsIn this study, we identified distinct ICD‐related modification patterns based on 158 TNBC cases in the TCGA‐TNBC cohort. We then investigated the possible correlation between ICD‐related modification patterns and TME cell infiltration characteristics in TNBC. By using univariate Cox and least absolute shrinkage and selection operator (LASSO) regression analysis, we created a risk scoring system (ICD score) to quantifiably evaluate the impact of ICD‐related modification patterns in individual TNBC patient. Two different ICD‐related modification patterns were found with significant differences in immune infiltration. Lower ICD score was correlated with higher immune infiltration, tumor mutational burden and significantly enriched in immune‐related pathways, indicating a strong ability to activate immune response, which might account for relatively favorable prognosis of TNBC patients and could serve as a predictor to select suitable candidates for immunotherapy. We used two independent cohorts, GSE58812 cohort and Metabric cohort to validate prognosis and immunohistochemistry for preliminary in vitro validation.ConclusionThis study evidenced that the ICD‐related modification patterns might exert pivotal roles in the immune infiltration landscape of TNBC and ICD score might act as potential predictors of prognostic assessment and immunotherapy response. This research provides unique insights for individualize immune treatment strategies and promising immunotherapy candidates screening.

show abstract

Section: Discussionmentioning

confidence: 76%

Development and verification of a novel immunogenic cell death‐related signature for predicting the prognosis and immune infiltration in triple‐negative breast cancer

Li,

Yang

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

show abstract

“…9). 82 Chen et al (2024) created melanin-loaded outer-membrane vesicles (OMVs) known as OMVMel by overexpressing tyrosinase in wild-type E. coli Nissle 1917 (EcN) cells. This allowed for the creation of melanin inside cells.…”

Section: Immunotherapymentioning

confidence: 99%

Breaking barriers in cancer treatment: nanobiohybrids empowered by modified bacteria and vesicles

Ijaz,

Khurshid,

et al. 2024

Nanoscale

View full text Add to dashboard Cite

show abstract

“…Thus, DAMP signaling may be essential to select patient-specific chemotherapy and tumor-specific therapeutic strategies ( Radogna et al, 2019 ). Notably, not all drugs are qualified inducers although some agents can cause potent intracellular stress and alter the relevant molecular markers ( Kroemer et al, 2022 ; Liu X. et al, 2023 ).…”

Section: Biology Of Icdmentioning

confidence: 99%

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Han,

Tian,

Zhai

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Immunotherapy has emerged as a promising cancer treatment option in recent years. In immune “hot” tumors, characterized by abundant immune cell infiltration, immunotherapy can improve patients’ prognosis by activating the function of immune cells. By contrast, immune “cold” tumors are often less sensitive to immunotherapy owing to low immunogenicity of tumor cells, an immune inhibitory tumor microenvironment, and a series of immune-escape mechanisms. Immunogenic cell death (ICD) is a promising cellular process to facilitate the transformation of immune “cold” tumors to immune “hot” tumors by eliciting innate and adaptive immune responses through the release of (or exposure to) damage-related molecular patterns. Accumulating evidence suggests that various traditional therapies can induce ICD, including chemotherapy, targeted therapy, radiotherapy, and photodynamic therapy. In this review, we summarize the biological mechanisms and hallmarks of ICD and introduce some newly discovered and technologically innovative inducers that activate the immune system at the molecular level. Furthermore, we also discuss the clinical applications of combing ICD inducers with cancer immunotherapy. This review will provide valuable insights into the future development of ICD-related combination therapeutics and potential management for “cold” tumors.

show abstract

Transforming Intratumor Bacteria into Immunopotentiators to Reverse Cold Tumors for Enhanced Immuno-chemodynamic Therapy of Triple-Negative Breast Cancer

Cited by 12 publications

References 64 publications

Development and verification of a novel immunogenic cell death‐related signature for predicting the prognosis and immune infiltration in triple‐negative breast cancer

Development and verification of a novel immunogenic cell death‐related signature for predicting the prognosis and immune infiltration in triple‐negative breast cancer

Breaking barriers in cancer treatment: nanobiohybrids empowered by modified bacteria and vesicles

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Contact Info

Product

Resources

About